GALNT17: A Potential Drug Target and Biomarker (G64409)

Target Name: GALNT17

NCBI ID: G64409

GALNT17

GALNT17: A Potential Drug Target and Biomarker

GALNT17, also known as N-acetylgalactosaminyltransferase-like protein 3, is a protein that is expressed in various tissues and cell types in the human body. It plays a crucial role in the synthesis and processing of N-acetylgalactosaminyltransferase (NAGT), a enzyme that is involved in the modification of neural cell-surface protein (NSFP) and other proteins. The dysfunction of NAGT has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Therefore, targeting NAGT and modulating its activity may provide new therapeutic approaches for the treatment of these disorders.

GALNT17 is a 21-kDa protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is a member of the glycoprotein family, which includes proteins that are involved in various cellular processes, including cell signaling, migration, and invasion. GALNT17 is characterized by a long N-terminal tail that is contains an N-acetylgalactosaminyl transferase active region and a C-terminus that is involved in the formation of a complex with other proteins.

GALNT17 is involved in the synthesis and processing of NAGT, which is an enzyme that is involved in the modification of NSFP and other proteins. NAGT is a transmembrane protein that is characterized by a N-terminal acidic amino acid that is involved in the formation of a N-acetyl group. This N-acetyl group is then modified by the addition of a hydrophobic amino acid, such as lysine, which results in the formation of NAGT. The C-terminus of NAGT is involved in the formation of a complex with other proteins, including the transcription factor nuclear factor E2F1, which is involved in the regulation of gene expression.

GALNT17 has been shown to play a role in the regulation of various cellular processes, including cell signaling, migration, and invasion. For example, GALNT17 has been shown to be involved in the regulation of the migration of cancer cells. In addition, GALNT17 has been shown to be involved in the regulation of cell signaling, including the regulation of the production of reactive oxygen species (ROS). ROS are highly reactive molecules that can damage cellular components and contribute to various diseases, including cancer, neurodegenerative diseases, and aging.

GALNT17 has also been shown to be involved in the regulation of inflammation. Inflammation is a critical response of the immune system to harmful stimuli, but it can also contribute to the development of various diseases, including autoimmune diseases and inflammatory bowel disease. shown to be involved in the regulation of the production of pro-inflammatory cytokines, such as interleukin-1尾 (IL-1尾) and interleukin-6 (IL-6), which are involved in the development of inflammatory diseases.

In conclusion, GALNT17 is a protein that is involved in various cellular processes, including cell signaling, migration, and inflammation. Its function as a drug target or biomarker makes it an attractive target for the development of new therapeutic approaches for the treatment of various neurological and psychiatric disorders. The modulation of NAGT activity may provide new insights into the pathophysiology of these disorders and suggest new targets for therapeutic intervention. Further research is needed to fully understand the role of GALNT17 in the development of these disorders and to develop effective therapies that target this protein.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 17

Functions: May catalyze the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor

The "GALNT17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets